

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of

9

Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

1646

Examiner Name

Attorney Docket No.

98,385-I

U.S. PATENT DOCUMENTS

Examiner Initials*	Citation No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
ERA	1	4,289,690		Pestka et al.	Sept. 15, 1981	
	2	4,560,649		Saxena et al.	Dec. 24, 1985	
	3	4,578,335		Urdal et al.	Mar. 25, 1986	
	4	4,609,546		Hiratani	Sept. 2, 1986	
	5	4,789,658		Yoshimoto et al.	Dec. 6, 1988	
	6	4,902,502		Nitecki et al.	Feb. 20, 1990	
	7	4,904,584		Shaw	Feb. 27, 1990	
	8	4,931,544		Katre et al.	Jun. 5, 1990	
	9	4,935,233		Bell et al.	Jun. 19, 1990	
	10	4,966,888		Saxena et al.	Oct. 30, 1990	
	11	5,089,261		Nitecki et al.	Feb. 18, 1992	
	12	5,116,964		Capon et al.	May 26, 1992	
	13	5,136,021		Dembinski et al.	Aug. 4, 1992	
	14	5,153,265		Shadle et al.	Oct. 6, 1992	
	15	5,162,430		Rhee et al.	5,162,430	
	16	5,214,131		Sano et al.	May 25, 1993	
	17	5,252,714		Harris et al.	Oct. 12, 1993	
	18	5,344,915		LeMaire et al.	Sep. 6, 1994	
	19	5,359,037		Wallach et al.	Oct. 25, 1994	
	20	5,382,657		Karasiewicz et al.	Jan. 17, 1995	
	21	5,395,760		Smith et al.	Mar. 7, 1995	
	22	5,478,925		Wallach et al.	Dec. 26, 1995	
	23	5,512,544		Wallach et al.	Apr. 30, 1996	
	24	5,605,690		Jacobs et al.	Feb. 25, 1997	
✓	25	5,610,279		Brockhaus et al.	Mar. 11, 1997	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Sheet 1 of 2

Application No.	09/898,234
Filing Date:	7-3-01
First Named Inventor	Hauptmann et al.,
Group Art Unit	
Examiner Name	
Attorney Docket No.	98,385-1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
EIA	26	5,633,145		Feldmann et al.	May 27, 1997	
	27	5,695,953		Wallach et al.	Dec. 9, 1997	
	28	5,712,155		Smith et al.	Jan. 27, 1998	
	29	5,808,029		Brockhaus et a.	Sep. 15, 1998	
	30	5,811,261		Wallach et al.	Sep. 22, 1998	
	31	5,843,791		Hauptmann et al.	Dec. 1, 1998	
✓	32	5,863,786		Feldmann et al.	Jan. 26, 1999	



FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Number ⁴	Kind Code ⁵ (if known)				
EIA	33	DE03910323A1					
	34	DE03913101.7					
EIA	35	DE0920282.8					
	36	EP0154316A2					
	37	EP0154316B1					
	38	EP0162699					
	39	EP0225579A3					
	40	EP0247860A2					
	41	EP0259863A2					
	42	EP0308378					
	43	EP0334165A2					
✓	44	EP0393438A2					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

 		Complete if Known	
		Application No.	09/898,234
		Filing Date:	7-3-01
		First Named Inventor	Hauptmann et al.,
		Group Art Unit	
		Examiner Name	
Sheet	9	Attorney Docket No.	98,385-l

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Number ⁴	Kind Code ⁵ (if known)				
EPA	45	EP0398327A1					
	46	EP0412486					
	47	EP0417563A2					
	48	EP0418014A1					
	49	EP0422339					
	50	EP0433900					
	51	EP0512528A2					
	52	EP0526905A2					
	53	GB2218101					
	54	GB2246569A					
	55	WO90/13575					
	56	WO91/03553					
	57	WO92/01002					
↓	58	WO92/07076					
	59	WO92/13095					
	60	WO92/15682					
	61	WO92/16221					
	62	WO92/01474					
	63	WO94/06476					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application No.	09/898,234
Filing Date:	7-3-01
First Named Inventor	Hauptmann et al.,
Group Art Unit	
Examiner Name	
Attorney Docket No.	98,385-I

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

64	Anderson et al., "Quantitative Filter Hybridisation," <i>Nucleic Acid Hybridization: A Practical Approach</i> pp. 73-111 (Hawes et al., eds., 1985).
65	Aggarwal et al., "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon," <i>Nature</i> 318:665-67 (1985).
66	Baglioni et al., "Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition," <i>J. Biol. Chem.</i> 260:13395-97 (1985).
67	Bakouche et al., "Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor," <i>J. Immunol.</i> 140:1142-47 (1988).
68	Beutler et al., "The Biology of Cachectin/TNF-A Primary Mediator of the Host Response", <i>Ann. Rev. Immunol.</i> 1989, 7:625-55
69	Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)," <i>EMBO J.</i> 8:2497-502 (1989).
70	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> 247:1306-10 (1990).
71	Brennan et al., "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis," <i>Lancet</i> 2:244-47 (1989).
72	Brockhaus, M. et al., <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-3131 (1990)
73	Capaldi et al., "Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis," <i>Biochem. Biophys. Res. Commun.</i> 74:425-33 (1977).
74	Colletti et al., "The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion," <i>Transplantation</i> 49:268-72 (1990).
75	Creasy, A. et al., <i>Proc. Natl. Acad. Sci. USA</i> 84:3293-3297 (1987)
76	Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor a Inhibitor," <i>Chemical Abstracts</i> 113(38760n):454 (1990).
77	Dembic et al., "Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences," <i>Cytokine</i> 2:231-37 (1990).
78	Engelmann et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>The Journal of Biological Chemistry</i> , Vol. 265.No.3 Issue of January 25, pp.1531-1536, 1990.
79	Engelmann et al., "Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity," <i>J. Biol. Chem.</i> 265:14497-504 (1990).
80	Espevik et al., "Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor," <i>J. Exp. Med.</i> 171:415-26 (1990).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

9

Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

Examiner Name

Attorney Docket No.

98,385-I

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

82	Evans, "The steroid and thyroid hormone receptor superfamily," <i>Science</i> 240:889-95 (1988).
83	Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85:8998-9002 (1988).
84	Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin..., <i>Proc. Natl. Acad. Sci. USA</i> 87:8781-8784 (1990).
85	Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," <i>BioTechnology</i> 8:343-346 (1990).
86	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-26 (1991).
87	Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 87:7380-84 (1990).
88	Grizzard et al., "Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus," <i>J. Clin. Endocrinol. Metab.</i> 58:535-43 (1984).
89	Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," <i>J. Cell Biochem. Suppl.</i> 15F:113(1991)
90	Hatakeyama et al., "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's," <i>Science</i> 244:551-56 (1989).
91	Hauser et al., "Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6," <i>Neurology</i> 40:1735-39 (1990).
92	Heller et al., "Complimentary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor," <i>Proc. Natl. Acad. Sci. USA</i> Vol. 87, pp. 6151-6155, August 1990.
93	Himmler et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein," <i>DNA Cell Biol.</i> 9:705-15 (1990).
94	Hofman et al., "Tumor necrosis factor identified in multiple sclerosis brain," <i>J. Exp. Med.</i> 170:607-12 (1989).
95	Hohmann, H.P. et al., <i>J. Biol. Chem.</i> 264:14927-14934
96	Israel et al. "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," <i>Immunol. Lett.</i> 12:217-224(1986).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	09/898,434
Filing Date:	7-3-01
First Named Inventor	Hauptmann et al.,
Group Art Unit	
Examiner Name	
Attorney Docket No.	98,385-I

Sheet 6 of 6 (use as many sheets as necessary)

OTHER DOCUMENTS (Including Prior Art, Title, Date, Pertinent Pages, Etc).

97	Kasukabe et al., "Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells," <i>J. Biol. Chem.</i> 263:5431-35 (1988).
98	Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-8335 (1990).
99	Kull et al., "Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 82:5756-60 (1985).
100	Lantz et al., "Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor," <i>J. Clin. Invest.</i> 86:1396-42 (1990).
101	Le et al., "Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities," <i>Lab. Invest.</i> 56:234-48 (1987).
102	Lee et al., "Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase," <i>Science</i> 239:1288-91 (1988).
103	Lehmann and Droge, "Demonstration of membrane receptors for human natural and recombinant 125I - labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity," <i>Eur. J. Biochem.</i> 158:1-5 (1986).
104	Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression," <i>Nature</i> 330:537-43 (1987).
105	Liao et al., "Identification of a specific interleukin 1 inhibitor in the urine of febrile patients," <i>J. Exp. Med.</i> 159:126-36 (1984).
106	Liao et al., "Characterization of a Human Interleukin 1 Inhibitor," <i>J. Immunol.</i> 134(6):3882-3886 (1995).
107	Liblau et al., "Tumor Necrosis Factor- α and Disease Progression in Multiple Sclerosis," <i>New Engl. J. Med.</i> 326(4):272-273 (1992).
108	Lindvall et al., "Modulation of the constitutive gene expression of the 55 kD tumor necrosis factor receptor in hematopoietic cells," <i>Biochem. Biophys. Res. Commun.</i> 172:557-63 (1990).
109	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor." <i>Cell</i> , Vol. 61 351-359 April 20, 1990
110	March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," <i>Nature</i> 315:641-47 (1985).
111	Neda, Hiroshi, "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," <i>Tumor Necrosis Factor, (TNF) Receptor</i> 56(2):305-17 (1987).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	09/898,234
Filing Date:	7-3-01
First Named Inventor	Hauptmann et al.,
Group Art Unit	
Examiner Name	
Attorney Docket No.	98,385-I

Sheet

of

9

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

- 113 Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA of the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," *The EMBO J.* 9(10):3269-3278 (1990).
- 114 Novick et al., "Soluble cytokine receptors are present in normal human urine," *J. Exp. Med.* 170:1409-14 (1989).
- 115 Novick et al., "Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography," *J. Chromatogr.* 510:331-37 (1990).
- 116 Olsson et al., "Isolation and characterization of a tumor necrosis factor binding protein from urine," *Eur. J. Haematol.* 42:270-75 (1989).
- 117 Peetre, C. et al., *Eur. J. Haematol* 41:414-419 (1988)
- 118 Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," *J. Exp. Med.* 174:1483-1489 (1991).
- 119 Piguet et al., "Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis," *J. Exp. Med.* 170:655-63 (1989).
- 120 Powell et al., "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," *Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine.* Pgs 355-369
- 121 Rhein et al., "Another Sepsis Drug Down: Immunex TNF Receptor," *Biotechnology Newswatch*, pg. 13 (Monday, October 4, 1993).
- 122 Ruddle et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," *J. Exp. Med.* 172:1193-1200 (1990).
- 123 Schall, T. J. et al., *Cell* 61:361-370 (1990)
- 124 Scheurich et al., "Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines," *Int. J. Cancer* 38:127-33 (1986).
- 125 Seckinger et al., "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor," *Proc. Natl. Acad. Sci. U. S. A.* 87:5188-92 (1990).
- 126 Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor," *J. Biol. Chem.* 264:11966-73 (1989).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JUL 27 2001

Sheet

of

9

Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

Examiner Name

Attorney Docket No.

98,385-I

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

127	Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor Alpha," J. Exp. Med. 167:1511-1516.
128	Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor a," J. Immunol. 139(5):1541-1545(1987).
129	Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor a," J. Immunol. 139(5):1446-1549(1987)
130	Selmaj et al., "Prevention of Chr-eae with Soluble TNF Receptor P55," J. Neurom.
131	Selmaj and Raine, "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination, Annals of Neurology Vol 30 No 5 November 1991.
132	Shimuzu et al., PNAS USA, 80:2112-2116 (1983).
133	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family Cellular and Viral Proteins, Reports, 1019-1023.
134	Smith et al., Science 248:1019-1023(1990)
135	Socher et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor," Proc. Natl. Acad. Sci. U. S. A. 84:8829-33 (1987).
136	Spinaz et al., "Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans," Am. J. Physiol. 259(5 Pt 2):R993-7 (1990).
137	Stauber and Aggarwal, "Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937," J. Biol. Chem. 264:3573-76 (1989).
138	Stauber. G. et al., J. Biol. Chem. 263(35):19098-19104.
139	Suffys et al., "Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity," Eur. J. Biochem. 178:257-65 (1988).
140	Suggs et al., "Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin," Proc. Natl. Acad. Sci. U. S. A. 78:6613-17 (1981).
141	The Cytokine Factsbook pp. 244-46 (Callard, ed., Academic Press, 1994).
142	Tracey et al., "Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation," J. Exp. Med. 167:1211-27 (1988).
143	Tracey et al., "Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia," J. Clin. Invest. 86:2014-24 (1990).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of

9

Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

Examiner Name

Attorney Docket No.

98,385-I

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

144	Tracey et al., "Physiological responses to cachectin," <i>Tumor Necrosis Factor and Related Cytotoxins</i> pp. 88-108 (Ciba Foundation Symposium 131, Wiley, Chichester, 1987).
145	Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," <i>Nature</i> 330:662-664(1987).
146	Tsujimoto et al., "Physiological responses to cachectin," "Tumor necrosis factor and related cytotoxins. Wiley, Chichester (Ciba Foundation Symposium 131), pp. 88-108" (1987).
147	Unglaub et al., "Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators," <i>J. Exp. Med.</i> 166:1788-97 (1987).
148	Vilcek et al., "Tumor necrosis factor receptor binding and mitogenic action in fibroblasts," <i>J. Cell Physiol.</i> 5:57-61 (1987).
149	Vitt et al., "Biological and Structural Characterization of the Tumor Necrosis Factor Receptor on Multiple Cell Types: Relationship to Function," <i>Fed. Proc. 78th Annual Meeting of the American Society of Biological Chemists</i> 46(6):2117 (1987).
150	Wallach et al., "Mechanisms which take part in regulation of the response to tumor necrosis factor," <i>Lymphokine Res.</i> 8:359-63 (1989).
151	Wallach, "Cell Surface and Soluble TNF Receptors, Tumor Necrosis Factor, 1992, pp 47- 57.
152	Wallach et al., "Regulation of the Response to Tumor Necrosis Factor," pp. 134-47 (Bonavida et al., eds., <i>Tumor Necrosis Factor/Cachectin and Related Cytokines Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg</i> , 1987).
153	Walsh et al., "Isolation and purification of ILS, an interleukin 1 inhibitor produced by human gingival epithelial cells," <i>Clin. Exp. Immunol.</i> 68:366-74 (1987).
154	Weber et al., "Production of an epidermal growth factor receptor-related protein," <i>Science</i> 224:294-97 (1984).
155	Yoshie et al., "Binding and Crosslinking of ¹²⁵ I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," <i>J. Biochem.</i> 100:531-541 (1986).
156	Ziegler, "Tumor necrosis factor in humans," <i>N. Engl. J. Med.</i> 318:1533-35 (1988).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Eileen B. O'Hara

1/21/03